William Blair Has Optimistic Outlook of TMDX Q1 Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities research analysts at William Blair upped their Q1 2025 earnings per share (EPS) estimates for TransMedics Group in a research report issued to clients and investors on Tuesday, October 29th. William Blair analyst R. Daniels now forecasts that the company will post earnings per share of $0.35 for the quarter, up from their previous estimate of $0.34. The consensus estimate for TransMedics Group’s current full-year earnings is $1.22 per share. William Blair also issued estimates for TransMedics Group’s Q2 2025 earnings at $0.44 EPS.

A number of other brokerages have also issued reports on TMDX. Oppenheimer reduced their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday. Canaccord Genuity Group decreased their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday. Morgan Stanley upped their target price on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. decreased their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $144.80.

TransMedics Group Trading Down 7.4 %

NASDAQ:TMDX opened at $81.92 on Wednesday. The company has a market capitalization of $2.73 billion, a P/E ratio of 87.15 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $177.37. The firm has a fifty day simple moving average of $144.20 and a 200-day simple moving average of $139.76.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the business earned ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fidelis Capital Partners LLC purchased a new stake in shares of TransMedics Group during the first quarter worth about $35,000. International Assets Investment Management LLC acquired a new stake in TransMedics Group in the 2nd quarter worth about $47,000. USA Financial Formulas acquired a new stake in TransMedics Group in the 3rd quarter worth about $55,000. J.Safra Asset Management Corp increased its stake in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,518,181 in the last three months. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.